Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan may predict dangerous clot return in lung patients

NCT ID NCT06372730

Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 665 people who had a pulmonary embolism (a blood clot in the lung) and are at intermediate risk of another clot. Researchers will use a special 3D lung scan (V/Q SPECT/CT) to measure leftover blockages in lung blood vessels. The goal is to see if this scan can predict who will have another clot within two years, which could help doctors decide who needs long-term blood thinners.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which patients need long-term blood thinners to prevent another dangerous clot.
What could go wrong
This is an observational study, not a treatment trial. The scan may not reliably predict recurrence, and results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 665 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years, * who experienced an objectively proven PE, * who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged. Exclusion Criteria: * Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship) * Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and patients admitted to a health or social establishment for purposes other than research * No Social security affiliation * Isolated DVT * Pregnant women and parturients * Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve) * Life expectancy \< 6 months * Any patients for whom there is a strong indication to treat longer than 6 months: * PE provoked by a major persistent factor (e.g. cancer) * Recurrent unprovoked PE PE provoked by a major transient risk factor (e.g. surgery with general anesthesia for greater than 30 min, confined to bed in hospital for at least 3 days with an acute illness, cesarean section) AND none of the following persistent factors : * BMI ≥ 30 * Chronic respiratory disease * Chronic inflammatory disease (e.g., ulcerative colitis, rheumatoid arthritis, etc.) * Hepatocellular insufficiency * Renal insufficiency with creatinine clearance \< 60 mL/min * Chronic or persistent immobilization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary embolism Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Les Sables d'Olonne

    RECRUITING

    Les Sables-d'Olonne, France, 85340, France

  • CH Quimper

    RECRUITING

    Quimper, France, 29000, France

  • CHD Vendée - La Roche sur Yon

    RECRUITING

    La Roche-sur-Yon, France, 85925, France

  • CHIC Toulon

    RECRUITING

    Toulon, France, 83056, France

  • CHU Amiens

    RECRUITING

    Amiens, France, 80054, France

  • CHU Angers

    ACTIVE_NOT_RECRUITING

    Angers, France, 49933, France

  • CHU Brest

    RECRUITING

    Brest, France, 29609, France

  • CHU St-Etienne

    RECRUITING

    Saint-Etienne, France, 42055, France

  • CHU Toulouse

    RECRUITING

    Toulouse, France, 31059, France

  • HIA Toulon

    RECRUITING

    Toulon, France, 83800, France

  • Hegp Ap-Hp

    RECRUITING

    Paris, France, 75015, France

  • Hôpital Louis MourierAP-HP

    RECRUITING

    Colombes, France, 92700, France

  • Kremlin-Bicêtre AP-HP

    ACTIVE_NOT_RECRUITING

    Le Kremlin-Bicêtre, France, 94270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.